A Multisite, Naturalistic, Observational Study of Transcranial Magnetic Stimulation for Patients With Pharmacoresistant Major Depressive Disorder

Dünner, David L.; Aaronson, Scott T.; Sackeïm, Harold A.; Janicak, Philip G.; Carpenter, Linda L.; Boyadjis, Terrence; Brock, David G.; Bonneh‐Barkay, Dafna; Cook, Ian A.; Lanocha, Karl; Solvason, H. Brent; Demitrack, Mark A.

doi:10.4088/jcp.13m08977

Cited by 124 publications

(99 citation statements)

References 39 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In large, naturalistic, observational follow up study, TMS demonstrated a sustained durability of effect over 12 months (Dunner et al 2014). To assess long term effectiveness of rTMS therapy patients are currently participating in follow up study.…”

Section: Discussionmentioning

confidence: 99%

EFFICACY, SAFETY AND TOLERABILITY OF AUGMENTATIVE rTMS IN TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD): A PROSPECTIVE COHORT STUDY IN CROATIA

et al. 2017

View full text Add to dashboard Cite

SUMMARY Background: An increasing body of research suggest that repetitive Transcranial Magnetic Stimulation (rTMS) is effective and safe treatment option for patients with major depressive disorder (MDD week. Our secondary outcomes were changes in Hamilton Anxiety (HAM-A) and WHOQOL-BREF scales. Results: After four weeks the changes of HAM-D17 and HAM-A results were significantly different between the group of patients treated by augmentative rTMS (48% and 53% decrease, respectively) and the group of patients treated by the standard therapy alone (24% and 30% decrease) (P=0.004, P=0.007). Absolute benefit increase defined as the difference between rates of remission (HAM-D17 ≤7) in rTMS and control group was 33% (P=0.001). Number of patients needed to treat with rTMS in order to

show abstract

Section: Discussionmentioning

confidence: 99%

EFFICACY, SAFETY AND TOLERABILITY OF AUGMENTATIVE rTMS IN TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD): A PROSPECTIVE COHORT STUDY IN CROATIA

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In the event of a positive test finding, clinicians are encouraged to discuss the findings with the patient and to consider adjunctive treatment options. For example, treatment options such as transcranial magnetic stimulation (TMS) or other neuromodulation interventions may be an augmentation strategy to address treatment non-response (Dunner et al, 2014). Due to the expense and time required to correctly implement such interventions, the PHQ-9 could be used to judiciously allocate scarce and expensive resources.…”

Section: Discussionmentioning

confidence: 99%

“…As such, depression severity is an excellent marker of treatment non-response among heterogeneous patient populations encountered in outpatient and inpatient settings. Accurate identification of individuals at risk of persistent depressive symptoms could lead to more rapid implementation of augmentation strategies to optimize clinical outcomes (Dunner et al, 2014;Holtzheimer and Mayberg, 2012). Biologically-based strategies for early identification of treatment resistant depression (TRD) have been explored including: neuroimaging (Konarski et al, 2009;Mayberg et al, 1997;Siegle et al, 2006Siegle et al, , 2012Stroup et al, 2006), genetic (Ising et al, 2009, Uher et al, 2009, electroencephalographic (Leuchter et al, 2009), and immune-related measures (Raison et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

Early identification of treatment non-response utilizing the Patient Health Questionnaire (PHQ-9)

Fowler

Patriquin

Madan

et al. 2015

Journal of Psychiatric Research

View full text Add to dashboard Cite

“…Studies suggest that antidepressant benefits of TMS can persist on the order of months (66,67), but relatively few studies have addressed optimal relapse prevention strategies to sustain benefits. Available evidence suggests that antidepressant initiation is critical to maintain remission (68).…”

Section: Transcranial Magnetic Stimulation Tms In Major Depressive DImentioning

confidence: 99%

Recent Developments in Noninvasive Neuromodulation for Mood and Anxiety Disorders

Rakesh

Lisanby

2015

Curr Behav Neurosci Rep

View full text Add to dashboard Cite

Noninvasive neuromodulation refers to a family of device-based interventions that apply electrical or magnetic fields, either at convulsive or subconvulsive levels, to the brain through the intact skull to modulate neural function. This is a rapidly evolving field, with new research emerging regarding the various roles that these devices can play both in studying the neural mechanisms underlying mood and anxiety disorders, and in treating pharmacoresistant conditions either on their own or in combination with other therapies. Each neuromodulation modality has its pros and cons and should be carefully chosen after weighing the risks and benefits. This manuscript reviews some of the most exciting developments in this field over the past year and emphasizes themes that are emerging as being important for these tools to fulfill their potential to transform how we study and treat mood and anxiety disorders. Key among these themes is the concept of how we understand the "dose" of the stimulation, and how exogenously applied fields interact with endogenous brain activity. Refining the concept of dose will ultimately be important in allowing clinicians and researchers to apply the procedure with precision to engage the targeted network to achieve the desired effects in each individual. The large parameter space defining dose of neuromodulation makes interpreting the literature on safety and efficacy challenging and highlights the need for clear and accurate reporting of the spatial, temporal, and contextual features of dosage to make the emerging literature base as informative as possible. Ultimately, the impact of noninvasive neuromodulation devices is potentially transformational given their utility in providing mechanistic insight into the circuitbased and oscillatory origins of mood and anxiety disorders, as well as providing therapeutic interventions rationally designed to target disease-related processes.

show abstract

A Multisite, Naturalistic, Observational Study of Transcranial Magnetic Stimulation for Patients With Pharmacoresistant Major Depressive Disorder

Cited by 124 publications

References 39 publications

EFFICACY, SAFETY AND TOLERABILITY OF AUGMENTATIVE rTMS IN TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD): A PROSPECTIVE COHORT STUDY IN CROATIA

EFFICACY, SAFETY AND TOLERABILITY OF AUGMENTATIVE rTMS IN TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD): A PROSPECTIVE COHORT STUDY IN CROATIA

Early identification of treatment non-response utilizing the Patient Health Questionnaire (PHQ-9)

Recent Developments in Noninvasive Neuromodulation for Mood and Anxiety Disorders

Contact Info

Product

Resources

About